N-acetyl Cysteine**

1.   van Zandwijk N. N-acetylcysteine for lung cancer prevention. Chest 1995;107:1437-41.
2.   Weinbroum AA, Rudick V, Ben-Abraham R, Karchevski E. N-acetyl-L-cysteine for preventing lung reperfusion injury after liver ischemia-reperfusion: a possible dual protective mechanism in a dose-response study. Transplantation 2000;69:853-9.
3.   Kelly GS. Clinical applications of N-acetylcysteine. Altern Med Rev 1998;3:114-27.
4.   Marchetti G, Lodola E, Licciardello L, Colombo A. Use of N-acetylcysteine in the management of coronary artery diseases. Cardiologia 1999;44:633-7.
5.   McKevoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
6.   Chyka PA, Butler AY, Holliman BJ, Herman MI. Utility of acetylcysteine in treating poisonings and adverse drug reactions. Drug Saf 2000;22:123-48.
7.   Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
8.   Kopke RD, Jackson RL, Coleman JKM, et al. NAC for noise: From the bench top to the clinic. Hear Res 2007;226:114-25.
9.   Lorito G, Giordano P, Prosser S, et al. Noise-induced hearing loss: a study on the pharmacological protection in the Sprague Dawley rat with N-acetyl-cysteine. Acta Otorhinolaryngol Ital 2006;26:133-9.
10.   Dickey DT, Muldoon LL, Kraemer DF, Neuwelt EA. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 2004;193:25-30.
11.   Duan M, Qiu J, Laurell G, et al, Dose and time-dependent protection of the antioxidant N-L-acetycysteine against impulse noise trauma. Hear Res 2004;192:1-9.
12. **Jellin JM, Gregory PJ, et al. Pharmacist’s letter/Prescriber’s Letter Natural Medicines Comprehensive Database. 12th ed. Stockton, CA: Therapeutic Research Faculty; 2009: P1214-1218.
13.   Kopke RD, Weisskopf PA, Boone JL, et al. Reduction of noise-induced hearing loss using L-NAC and salicylate in the chinchilla. Hear Res 2000;149:138-146.

Milk Thistle**

1.   Venkataramanan R, Ramachandran V, Komoroski BJ, et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000;28:1270-3.
2.   Boerth J, Strong KM. The clinical utility of milk thistle (Silybum marianum) in cirrhosis of the liver. J Herb Pharmacother 2002;2:11-7.
3.   Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139-43.
4.   Velussi M, Cernigoi AM, De Monte A, et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997;26:871-9. 5.   Huseini HF, Larijani B, Heshmat R, et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 2006;20;1036-9.
6.   Feher J, Deak G, Muzes G, et al. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases]. [Article in Hungarian]. Orv Hetil 1989;130:2723-7.
7.   Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9:105-13.
8.   Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind, controlled study. Scand J Gastroenterol 1982;17:517-21.
9.   Bunout D, Hirsch S, Petermann M. [Controlled study of the effect of silymarin on alcoholic liver disease.] [Article in Spanish]. Rev Med Chil 1992;120:1370-5.
10.   Trinchet JC, Coste T, Levy VG. [Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients]. [Article in French]. Gastroenterol Clin Biol 1989;13:120-4.
11.   Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998;28:615-21.
12.   Rambaldi A, Jacobs B, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2005;2:CD003620.
13   Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 1993;31:456-60.
14.   Tanamly MD, Tadros F, Labeeb S, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis 2004;36:752-9.
15.   Szilard S, Szentgyorgyi D, Demeter I. Protective effect of Legalon in workers exposed to organic solvents. Acta Med Hung 1988;45:249-56..
16.   Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 1999;290:1375-83.
17. **Jellin JM, Gregory PJ, et al. Pharmacist’s letter/Prescriber’s Letter Natural Medicines Comprehensive Database. 12th ed. Stockton, CA: Therapeutic Research Faculty; 2009: P1190-1193.
18.   Zhu W, Zhang JS, Young CY. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 2001;22:1399-403

Alpha-lipoic acid**

1.   Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Rad Biol Med 1995;19:227-50.
2.   Vincent HK, Bourguignon CM, Vincent KR, Taylor AG. Effects of alpha-lipoic acid supplementation in peripheral arterial disease: a pilot study. J Alt Complement Med 2007;13:577-84.
3.   Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22:359-78.
4.   Packer L. Antioxidant properties of lipoic acid and its therapeutic effects in prevention of diabetes complications and cataracts. Ann N Y Acad Sci 1994;738:257-64. 5.   Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Rad Biol Med 1995;19:227-50.
6.   Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid. Diabetes Care 2003;26:770-6.
7.   Fuchs J, Schofer H, Milbradt R, et al. Studies on lipoate effects on blood redox state in human immunodeficiency virus infected patients. Arzneimittelforschung 1993;43:1359-62.
8.   Baur A, Harrer T, Peukert M, et al. Alpha-lipoic acid is an effective inhibitor of human immuno-deficiency virus (HIV-1) replication. Klin Wochenschr 1991;69:722-4. 9.   Conlon BJ, Aran JM, Erre JP, Smith DW. Attenuation of aminoglycoside-induced cochlear damage with the metabolic antioxidant alpha-lipoic acid. Hear Res 1999;128:40-4.
10. *Jellin JM, Gregory PJ, et al. Pharmacist’s letter/Prescriber’s Letter Natural Medicines Comprehensive Database. 12th ed. Stockton, CA: Therapeutic Research Faculty; 2009: P57-60.
11.   Gurer H, Ozgunes H, Oztezcan S, Ercal N. Antioxidant role of alpha-lipoic acid in lead toxicity. Free Rad Biol Med 1999;27:75-81.
12.   Altenkirch H, Stoltenburg-Didinger G, Wagner HM, et al. Effects of lipoic acid in hexacarbon-induced neuropathy. Neurotoxicol Teratol 1990;12:619-22.
13.   Vilas GL, Aldonatti C, San Martin de Viale LC, Rios de Molina MC. Effect of Alpha-lipoic acid amide on hexachlorobenzene porphyria. Biochem Mol Biol Int 1999;47:815-23.

Curcumin**

1.   Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease (letter). J Clin Psychopharmacol 2008;28:110-3.
2.   Araujo CC, Leon LL. Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 2001;96:723-8.
3.   Antony S, Kuttan R, Kuttan G. Immunomodulatory activity of curcumin. Immunol Invest 1999;28:291-303.
4.   Zhang F, Altorki NK, Mestre JR, et al. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999;20:445-51.
5.   Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food Chem Toxicol 2002;40:1091-7.
6.   Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58.
7.   Deeb D, Xu YX, Jiang H, et al. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2003;2:95-103.
8. *Jellin JM, Gregory PJ, et al. Pharmacist’s letter/Prescriber’s Letter Natural Medicines Comprehensive Database. 12th ed. Stockton, CA: Therapeutic Research Faculty; 2009: P1684-1686.
9.   Thaloor D, Singh AK, Sidhu GS, et al. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ 1998;9:305-12.

Schisandra Berry**

1. *Jellin JM, Gregory PJ, et al. Pharmacist’s letter/Prescriber’s Letter Natural Medicines Comprehensive Database. 12th ed. Stockton, CA: Therapeutic Research Faculty; 2009: P1505-1508.
2.  Upton R, ed. Schisandra Berry: Analytical, quality control, and therapeutic monograph. Santa Cruz, CA: American Herbal Pharmacopoeia 1999;1-25.
3.  Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and
4. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996.
5.  McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
6.  Lee IS, Jung KY, Oh SR, et al. Structure-activity relationships of lignans from Schisandra chinensis as platelet activating antagonists. Biol Pharm Bull 1999;22:265-7.
7.  Fetrow CW, Avila JR. Professional's Handbook of Complementary & Alternative Medicines. 1st ed. Springhouse, PA: Springhouse Corp., 1999.
8. Iwata H, Tezuka Y, Kadota S, et al. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 2004;32:1351-8.

* These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

1.     What are the health benefits of taking Liver Max-Protector?

Liver Max-Protector is specially formulated by best doctors for protecting our body (including liver) from damages caused by toxins, poisons, viruses, alcohol and certain drugs. It helps improve liver and other organ function, and maintain a healthy immune system.*

2.     Is it best to take the Liver Max-Protector with meal?

Yes, it is always best to take your nutritional supplements with a meal. This allows your body to absorb the nutrients more efficiently and with a greater degree of tolerance.*

3.     How many Brain Max-Health capsules should I take a day?

For adult, take 1-2 capsule(s) with meal a day.

* These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.